尤瑞克林联合丁苯酞氯化钠注射液治疗急性进展型脑梗死的疗效观察

Therapeutic effect of kallidinogenase combined with butylphthalide and sodium chloride injection on acute progessive cerebral infarction

目的探讨尤瑞克林联合丁苯酞氯化钠注射液治疗急性进展型脑梗死的临床疗效和安全性。方法选择本院2013年1月-2016年3月治疗的急性进展型脑梗死患者60例,随机分为治疗组30例,对照组30例,对照组给予尤瑞克林治疗,治疗组给予尤瑞克林联合丁苯酞氯化钠注射液,评价2组患者在治疗前、治疗第8日、第15日临床疗效、神经功能缺损程度的恢复情况及日常生活能力评分等变化。结果治疗第8日,第15日,治疗组临床有效率为93.3%,近期治愈率达73.3%,神经功能缺损和日常生活能力的改善与对照组比较差异均有统计学意义(P<0.01)。结论尤瑞克林联合丁苯酞氯化钠注射液能明显改善进展型脑梗死患者神经功能缺损程度和日常生活能力,临床疗效好,2组均未出现明显不良反应,尤瑞克林联合丁苯酞注射液治疗急性进展型脑梗死安全有效。

Objective To determine the clinical efficacy and safety of kallidinogenase combined with butylphthalide and sodium chloride injection for acute progressive cerebral infraction. Methods A total of 60 patients with acute progressive cerebral infarction from January 2013 to March 2016 were randomly divided into 2 groups： the treatment group treated with kallidinogenase combined butylphthalide and sodium chloride injection （n = 30）, while the control group treated with kallidinogenase （n = 30）. The clinical efficacy on day 15, and neurological function and restoration of invalidity were observed. Results The kallidinogenase combined with butylphthalide and sodium chloride injection group significantly reduced the neurological deficits and the effeci- tive rate reached 93.3%, and the recent curative rate was 73.3%, as cmpared with those of the control group on day 8 and day 15. The neurological function and restoration of invalidity were elevated markedly compared with those in the control group （P 〈 0.01）. Conclusion Kallidinogenase combined with butylphthalide and sodium chloride injection can significantly restore the neuroogical invalidity in acute progressive cerebral infarction. Kallidinogenase combined with butylphthalide and sodium chloride injection is safe and effective.